Table 3.
Treatmenta | Splenocytes (×106)b | CD4+ (%) | CD4+ (×106) | CD4+Foxp3+ (%) | Treg/spleen (×106) |
Isotype | 46.3 ± 0.8 | 9.6 ± 1.1 | 4.5 ± 0.7 | 14.1 ± 0.4 | 0.62 ± 0.1 |
Anti-CD20 | 47.4 ± 0.2 | 23.2 ± 0.8 | 10.9 ± 0.6 | 12.3 ± 0.4 | 1.36 ± 0.1 |
Isotype | 57.6 ± 0.2 | 17 ± 0.5 | 9.8 ± 0.6 | 10.9 ± 0.8 | 1.10 ± 0.1 |
Anti-CD20 | 52.7 ± 0.2 | 26.4 ± 1.9 | 14.1 ± 1.4 | 11.3 ± 0.7 | 1.53 ± 0.2 |
Foxp3GFP NOD.H-2h4 mice were given two injections of 125 μg anti-CD20 IgG2a or isotype control at 10 and 16 days of age (lines 1 and 2) or at 6 weeks of age (lines 3 and 4). Foxp3+ Treg in spleens were determined 12 days later, i.e. mice in lines 1 and 2 were 4 weeks old and mice in lines 3 and 4 were almost 8 weeks old. At the time of assay, isotype controls in line 1 had 60.8 ± 1.2% CD19+ B cells compared with 10.5 ± 1.5 in anti-CD20-treated mice and mice in line 3 had 59.4 ± 0.9% CD19+ B cells compared with 18.4 ± 3.1 in age-matched anti-CD20-treated mice (line 4).
Mean ± SEM of six to seven mice per group. P < 0.01 for anti-CD20-treated compared with control mice in lines 1 and 2 and P > 0.05 for anti-CD20 compared with controls in lines 3 and 4.